Estamos no ar no ! Saiba mais
6,25 USD
-0,05
0,79%
No fechamento Atualizado 16 de out. 16:00 EDT
1 dia
-0,79%
5 dias
1,3%
1 mês
21,83%
3 meses
-6,16%
6 meses
-5,16%
No acumulado do ano
-5,73%
1 ano
-26,56%
5 anos
-84,87%
10 anos
-88,91%
 

Sobre: Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

Funcionários: 753

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 10%
Neutro 60%
Negativo 30%
Neutro
Business Wire
ontem
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
Neutro
Business Wire
há 16 dias
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
Neutro
Zacks Investment Research
mês passado
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Positivo
Zacks Investment Research
há 2 meses
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Negativo
Zacks Investment Research
há 2 meses
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Neutro
Zacks Investment Research
há 2 meses
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Neutro
Seeking Alpha
há 2 meses
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Negativo
MarketBeat
há 2 meses
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen Q2 Earnings Call Highlights
Negativo
Zacks Investment Research
há 2 meses
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Neutro
Business Wire
há 2 meses
Inogen Announces Second Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.
Inogen Announces Second Quarter 2026 Financial Results
Gráficos de preços implementados com Lightweight Charts™